Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor.

Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor.

Item
http://www.wikidata.org/entity/Q40032572
Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics.Aptamers from cell-based selection for bioanalytical applicationsClinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancerCurrent status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistancePrimary trastuzumab resistance: new tricks for an old drug.Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatmentSignal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR familyThe combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity.V-ATPase inhibition overcomes trastuzumab resistance in breast cancer.Quantitating ADCC against adherent cells: Impedance-based detection is superior to release, membrane permeability, or caspase activation assays in resolving antibody dose response.Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy.
P2860

Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor.

Item
http://www.wikidata.org/entity/Q40032572
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Trastuzumab decreases the numb ...... sistance of the primary tumor.
@en
type
label
Trastuzumab decreases the numb ...... sistance of the primary tumor.
@en
prefLabel
Trastuzumab decreases the numb ...... sistance of the primary tumor.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
Trastuzumab decreases the numb ...... sistance of the primary tumor.
@en
P2093
P304
P31
P356
10.1016/J.CANLET.2007.10.043
P407
P433
P478
P50
P577
P5875
P698